CHICAGO — Roche had previously announced the failure of its closely tracked anti-TIGIT immunotherapy in a study involving patients with small cell lung cancer. But new details revealed for the first time Sunday showed the drug, called tiragolumab, had no activity at all — adding to the questions about its future.
In the study called SKYSCRAPER-02, tiragolumab combined with a two-drug standard of care performed worse than the control arm. The tiragolumab regimen elevated the risk of tumors progressing by 11% compared to standard therapy alone, which consisted of Tecentriq, Roche’s currently approved PD-L1 checkpoint inhibitor, and chemotherapy.
Create a display name to comment
This name will appear with your comment